Lupin gets US FDA tentative approvals for 2 generics

Key development: two tentative approvals in March 2026

Lupin Limited has reported two separate tentative approvals from the United States Food and Drug Administration (US FDA) in March 2026, adding to its pipeline of US-focused generic filings. The company disclosed tentative approval for Sugammadex Injection on March 31, 2026, and for Pitolisant Tablets on March 25, 2026. Both approvals relate to Abbreviated New Drug Applications (ANDAs), a key route for generic launches in the US market. A tentative approval typically indicates the product has met the agency’s requirements for quality and bioequivalence but may still be subject to patent or exclusivity constraints before final approval. Lupin’s updates were issued in announcements referencing its listings on BSE and NSE. The developments are relevant for investors tracking Lupin’s US portfolio, where regulatory milestones can shape the pace of product additions. The filings also arrive against the backdrop of an FDA notice withdrawing approvals related to obeticholic acid products, including a Lupin generic.

Sugammadex Injection: what Lupin received

On March 31, 2026, Lupin said it received tentative approval from the US FDA for its ANDA for Sugammadex Injection. The filing covers two presentations: 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) single-dose vials. Lupin stated the product is bioequivalent to Merck’s Bridion Injection. The drug is indicated for reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide. The labeling referenced in the announcement includes use in adults and pediatric patients aged 2 years and older undergoing surgery. Lupin did not disclose a launch date, commercial timeline, or expected revenue contribution in the provided text. It also did not specify the manufacturing site for sugammadex in the excerpt.

Pitolisant Tablets: Nagpur facility named

In a separate announcement dated March 25, 2026, Lupin said it received tentative approval from the US FDA for its ANDA for Pitolisant Tablets in strengths of 4.45 mg and 17.8 mg. The company stated this product would be manufactured at Lupin’s Nagpur facility in India. Lupin said the US FDA has tentatively approved the product as bioequivalent to Wakix for the indication in the approved labeling. As with the sugammadex update, Lupin did not provide a specific timeline for final approval or market entry in the excerpt. The inclusion of the manufacturing location is notable because it links the regulatory milestone to a specific Indian site.

Regulatory context: tentative approval versus final approval

The announcements describe “tentative approval,” which is distinct from full approval to market in the US. Lupin’s language focuses on bioequivalence and alignment with the reference product’s approved labeling. The provided text does not state the reason for tentative status for these two products, and it does not mention any specific patent or exclusivity barriers. Still, tentative approval generally means the application meets US FDA standards but cannot be marketed until remaining legal or regulatory conditions are resolved. For readers tracking US generic pipelines, tentative approvals are often treated as progress indicators rather than immediate launch signals. Lupin has used similar phrasing in other updates, positioning these ANDA outcomes as part of its broader portfolio build-out.

FDA withdrawal notice: obeticholic acid approvals pulled

Alongside Lupin’s product updates, the provided material includes an FDA notice withdrawing approvals for obeticholic acid products. The notice states that approval of NDA 207999 for OCALIVA (obeticholic acid) tablets, 5 mg and 10 mg, and ANDAs 214862, 214980, and 215017 for obeticholic acid tablets, 5 mg and 10 mg, is withdrawn under Sec. 314.150(d). The notice further states that distribution into interstate commerce without an approved application is illegal and subject to regulatory action. It lists Intercept’s OCALIVA tablets, and generic obeticholic acid tablets associated with Apotex, Lupin, and MSN. The excerpt does not provide dates for the withdrawal decision beyond the text shown, nor does it describe Lupin’s response. It also does not quantify any sales exposure or inventory impact.

Other Lupin US FDA milestones cited in the text

The provided material references several additional US FDA decisions involving Lupin over 2023-2025 and other periods mentioned without precise dates. On January 9, 2025, Lupin said it received tentative approval for Ivacaftor Oral Granules (25 mg, 50 mg, and 75 mg per unit dose packet) as a generic equivalent of Kalydeco Oral Granules of Vertex Pharmaceuticals. On November 21, 2023, Lupin said it received tentative approval for Dapagliflozin Tablets (5 mg and 10 mg) as a generic equivalent of AstraZeneca’s Farxiga tablets, and the company stated the product will be manufactured at its Pithampur facility in India. The text also references tentative approval for Selexipag for Injection, 1800 mcg/vial, single-dose vial, and notes manufacturing at Lupin’s Nagpur facility. Separately, the excerpt mentions an earlier October tentative approval for apalutamide tablets, 60 mg, a generic equivalent of Erleada tablets, 60 mg of Janssen Biotech, Inc.

Snapshot table: products, references, and regulatory status

Market impact: what is known from the disclosures

Lupin’s announcements do not include guidance on revenue, profitability, or expected launch timing for either sugammadex or pitolisant. No market-size figures, pricing details, or competitive landscape metrics are provided in the text. As a result, the measurable market impact from these two tentative approvals cannot be quantified from the disclosed information alone. What can be stated is that the approvals add to Lupin’s list of ANDA outcomes in the US, and that at least one of the new products, pitolisant tablets, is tied to the Nagpur facility. On the risk side, the FDA withdrawal notice explicitly flags that distribution of obeticholic acid products without an approved application is illegal and subject to regulatory action. The excerpt does not state whether Lupin was distributing the product at the time, nor does it specify remedial steps.

Analysis: why these updates matter for Lupin’s US portfolio

The March 2026 updates reinforce Lupin’s continued push across injectables and oral solids for the US generic market. Sugammadex is positioned as a hospital-use injectable tied to surgical anesthesia workflows, while pitolisant is an oral product referenced against Wakix, indicating Lupin’s interest in differentiated generic opportunities beyond commoditised molecules. Naming Indian sites, such as Nagpur and Pithampur in other approvals, also matters because US supply reliability often hinges on plant compliance and regulatory continuity. At the same time, the obeticholic acid withdrawal excerpt is a reminder that FDA actions can also move in the opposite direction, affecting approvals already granted. For investors, the combination of pipeline progress and regulatory reversals underscores why product-level regulatory tracking is essential when evaluating US growth narratives. The disclosures, however, do not provide enough numbers to estimate earnings sensitivity.

What to watch next

The next concrete milestone for both sugammadex and pitolisant will be movement from tentative approval to final approval, subject to any remaining conditions not detailed in the text. Investors may also track any further communication from Lupin regarding the FDA withdrawal notice related to obeticholic acid products, including compliance steps or portfolio adjustments, if disclosed. Separately, Lupin’s broader stream of US filings and approvals, including products manufactured at Nagpur and Pithampur, suggests the company will continue to use regulatory updates to signal execution in its US pipeline. Any future announcements are likely to clarify launch readiness, manufacturing allocation, or status changes at the product level.